WELCOME TO The PHARMACEUTICAL REPORT
Container Closure Integrity Testing (CCIT) testing for the pharmaceutical industry
January 2, 2019
I'm For Real
Enter your details once to access all our information and resources
KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs.
whitePaper | January 3, 2022
There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs
whitePaper | April 7, 2020
The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.
whitePaper | January 1, 2020
Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.
whitePaper | February 11, 2021
Welcome to Pharmaprojects’ 2021 review of trends
in pharmaceutical R&D. For almost 30 years now,
I’ve been taking an annual look at the evolution
of pharma R&D, and in this article I’ll examine
the state of play at the start of 2021.
whitePaper | February 5, 2022
Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains
ensure that the right amount of medicine, with acceptable quality, will reach the customers in need
whitePaper | May 22, 2021
One of the key roles of the generic and biosimilar medicines industry is specifically to promote
the widest possible access to affordable medicines with high quality, safety, and efficacy for
patients globally by introducing competition into the markets. Despite the many hurdles, the
generic medicines companies have clearly lived up to the challenges posed by the pandemic
as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the
outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive
Care Units to ventilate critically ill COVID patients. It is also providing most of the quality
medicines dispensed around the world, especially for increasingly prevalent chronic diseases
and is therefore a strong contributor to health outcomes globally.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE